小剂量HA方案化疗老年急性髓系白血病疗效观察  

Efficacy of low-dose HA regimen in the treatment of elderly acute leukemia

作　　者：何春玲[1] 董昌虎[1] 张云志[1] 姚松夏 孟凡超[1] 王刚[1] 闫昱江[1] 张杨[1] 

机构地区：[1]陕西中医学院第二附属医院,咸阳712000

出　　处：《陕西医学杂志》2010年第10期1380-1381,共2页Shaanxi Medical Journal

摘　　要：目的:探讨由小剂量高三尖杉脂碱(Har)和阿糖胞苷(Ara-C)组成HA化疗方案,在老年急性髓系白血病(AML)治疗中的疗效。方法:对19例60岁及以上AML患者,采用Har1~2mg/d,第1~14d,Ara-C 25~50mg/d,第1~14d,静脉滴注,间隔21~28d再行第2疗程化疗。结果:19例中完全缓解(CR)10例,部分缓解(PR)4例,未缓解(NR)5例,不良反应主要为骨髓抑制和粒细胞缺乏所致的感染,无早期死亡病例。结论:小剂量HA方案可诱导白血病细胞分化和促进凋亡,对不能耐受标准剂量化疗的老年人AML患者,具有一定优势,既可减少标准剂量化疗所致的化疗相关性死亡,又可在一定程度上延长患者的生存期。Objective：To investigate the efficacy of low-dose HA regimen（harringtonine and cytarabine）for elderly acute leukemia.Methods： A total of 19 AML elderly patients were enrolled.Eleven patients were male,and 8 were female.The HA regimen contained harringtonine（1~2mg/d,days 1 to 14） and cytarabine（25mg^50mg/d,days 1 to 14）,Interval of days 21 to 28 for the second chemotherapy.Results：In 19 elderly patients with acute leukemia,the total complete remission（CR） rate of them was 52.63%（10/19）,partial remission rate of them was 21.05%（4/19）,non-remission rate of them was 26.32%（5/19）,myelosuppression and infection due to neutropenia were the most frequent adverse effects,the early death were not observed in all patients.Conclusion： Low-dose HA regimen for elderly acute leukemia has certain advantages in the remission induction therapy,that can not tolerate the standard-dose chemotherapy in elderly patients with acute leukemia,which can reduce the related death of standard-dose chemotherapy,and to extend the survival of patients with the advantage of reducing early mortality.

关 键 词：白血病 髓样 急性/药物疗法 三尖杉脂碱/治疗应用 阿糖胞苷/治疗应用 老年人 

分 类 号：R551.3[医药卫生—血液循环系统疾病]